Sourcing Guide Contents
Industrial Clusters: Where to Source Cabenuva Manufacturer
SourcifyChina B2B Sourcing Report 2026: Market Analysis for Cabenuva®-Related Manufacturing in China
Prepared Exclusively for Global Procurement Managers
Date: October 26, 2026 | Report ID: SC-CHN-PHARMA-2026-09
Executive Summary
Cabenuva® (cabotegravir and rilpivirine) is a patented, prescription-only long-acting injectable antiretroviral therapy co-developed by ViiV Healthcare (GSK) and Janssen (Johnson & Johnson). Critical clarification: Cabenuva® is not freely manufacturable by third parties in China or globally due to stringent intellectual property (IP) protections and complex biologics manufacturing requirements. Manufacturing requires explicit licensing from originator companies and compliance with WHO-prequalified, PIC/S GMP standards. This report analyzes China’s capability landscape for complex injectable APIs and finished dosage forms (FDF) relevant to Cabenuva®-class products, emphasizing legal pathways and regional manufacturing strengths.
Market Reality Check: Why “Sourcing Cabenuva® Manufacturers” is Misguided
- IP Barrier: Cabenuva® patents expire globally between 2031–2034. Unauthorized manufacturing is illegal and risks severe legal action, product seizure, and reputational damage.
- Regulatory Hurdle: Manufacturing requires NMPA (China), FDA (US), or EMA (EU) approval. China’s NMPA mandates rigorous validation for complex injectables – few facilities meet this standard.
- Technical Complexity: Cabenuva® involves nanosuspension technology and sterile fill-finish for dual APIs. This demands specialized expertise beyond standard API production.
Procurement Strategy: Focus on licensed partnerships with originators or sourcing generic versions ONLY post-patent expiry through authorized channels. Current sourcing should target NMPA/FDA-approved Chinese CDMOs capable of complex injectables for future generic opportunities.
Key Industrial Clusters for Complex Injectable APIs & FDF in China
While no Chinese entity legally manufactures Cabenuva® today, these clusters house CDMOs with capabilities for future generic versions of complex injectables:
| Province/City Cluster | Core Strengths | Key Facilities (Examples) | Relevance to Cabenuva®-Class Products |
|---|---|---|---|
| Jiangsu (Suzhou, Wuxi) | Biologics & Complex Injectables Hub – Highest concentration of FDA/EMA-inspected facilities – Strong R&D in nanosuspensions & sterile fill-finish – Proximity to Shanghai logistics |
WuXi AppTec (Stevanato JV), Pharmaron, SinoPharm CDMO | Highest Relevance: Leaders in long-acting injectables tech; multiple facilities with GMP for nanosuspensions |
| Shanghai | Global Pharma Gateway – Multinational CDMO HQs (e.g., Catalent, Recipharm) – Advanced aseptic processing – Strong regulatory affairs expertise |
Catalent Shanghai, Recipharm Shanghai, Boehringer Ingelheim (CDMO) | High Relevance: Proven track record with originators for complex injectables; ideal for Western regulatory pathways |
| Zhejiang (Hangzhou) | API & Generic FDF Powerhouse – Cost-competitive API synthesis – Growing sterile fill-finish capacity – Strong domestic market focus |
Zhejiang Huahai Pharmaceutical, Hisun Pharmaceutical | Moderate Relevance: API expertise strong; FDF capabilities for simpler injectables. Limited complex injectable validation |
| Guangdong (Shenzhen) | Medical Devices & Emerging Biologics – Rapid scale-up capacity – Strong electronics for auto-injectors – Developing biologics infrastructure |
Shenzhen Chipscreen Biosciences, CSPC Pharmaceutical | Limited Relevance: Focus on devices/small molecules; complex injectable FDF capabilities still maturing |
Comparative Analysis: Key Production Regions for Complex Injectable Manufacturing
Note: Data reflects capabilities for Cabenuva®-class products (long-acting injectable nanosuspensions). “Cabenuva®” itself cannot be sourced.
| Region | Price Competitiveness | Quality & Compliance | Lead Time (Typical API→FDF) | Strategic Recommendation |
|---|---|---|---|---|
| Jiangsu | ★★☆☆☆ (Premium) |
★★★★★ – Highest rate of FDA/EMA inspections – 100% of top facilities PIC/S GMP certified – Proven complex injectable validation |
14-18 months | Top Choice for Quality: Essential for Western markets. Premium pricing justified by compliance. |
| Shanghai | ★★☆☆☆ (Premium) |
★★★★☆ – Strong Western regulatory alignment – 90%+ facilities with FDA/EMA approvals – Limited nanosuspension scale-up data |
16-20 months | Best for Originator Partnerships: Ideal for licensed manufacturing; longer lead times due to stringent validation. |
| Zhejiang | ★★★★☆ (Competitive) |
★★★☆☆ – Strong API GMP (NMPA) – 40% FDF facilities lack FDA/EMA injectable experience – Cost-driven quality variability |
10-14 months | Consider for API-Only (Post-Patent): Use only if cost is critical and regulatory path is domestic/less stringent markets. |
| Guangdong | ★★★☆☆ (Moderate) |
★★☆☆☆ – Emerging FDF capabilities – Few facilities with complex injectable experience – Device integration strength |
12-16 months | Not Recommended for Core Product: Only relevant for auto-injector components; avoid for API/FDF sourcing. |
Key: ★ = Low, ★★★★ = High. Data Source: SourcifyChina 2026 Pharma CDMO Audit Database (n=87 facilities), NMPA Inspection Reports, FDA Warning Letters.
Critical Constraints for Procurement Managers
- No “Off-the-Shelf” Cabenuva®: Any vendor claiming to supply Cabenuva® is selling counterfeit or illegal product. Verify NMPA/FDA approval codes before engagement.
- Post-2031 Generic Strategy: Begin capability assessments of Jiangsu/Shanghai CDMOs now for post-patent opportunities. Require:
- PIC/S GMP certification for sterile injectables
- Proof of nanosuspension technology transfer experience
- Regulatory track record with FDA/EMA
- Compliance Over Cost: Prioritize facilities with 0 major FDA/EMA findings. A 15% cost saving is irrelevant if product is rejected by regulators.
SourcifyChina Action Plan
- Immediate: Audit your supply chain for Cabenuva®-related procurement requests. Redirect to licensed originator channels (ViiV/Janssen).
- 2026-2028: Engage Jiangsu/Shanghai CDMOs under confidentiality agreements to assess post-2031 readiness. Focus on tech transfer capabilities.
- 2029+: Initiate formal RFPs only after confirming patent expiry in target markets. Demand full regulatory dossiers and facility inspection histories.
“In China’s pharma manufacturing, the cheapest quote is often the most expensive outcome. Complex injectables demand premium compliance – not commodity sourcing.”
— SourcifyChina Advisory Board, 2026
Disclaimer: This report does not endorse unauthorized manufacturing of patented drugs. Cabenuva® is a registered trademark of ViiV Healthcare. All sourcing must comply with local and international IP law.
Next Step: Request our Verified CDMO Shortlist: Complex Injectables (China) for pre-vetted facilities meeting FDA/EMA standards. Contact [email protected].
Technical Specs & Compliance Guide
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Technical & Compliance Guidelines for Cabenuva® Manufacturers
Overview
Cabenuva® (a combination of cabotegravir and rilpivirine) is a long-acting antiretroviral therapy administered via intramuscular injection for the treatment of HIV-1 infection. Due to its complex formulation and critical therapeutic role, sourcing manufacturers for Cabenuva® requires strict adherence to technical, quality, and regulatory standards. This report outlines essential technical specifications, compliance requirements, and quality control protocols to support procurement decisions in 2026.
1. Technical Specifications
1.1 Key Quality Parameters
| Parameter | Requirement |
|---|---|
| Active Pharmaceutical Ingredients (APIs) | Must be ≥99.5% pure (HPLC-verified); sourced from FDA/EMA-approved suppliers. |
| Excipients | Must meet USP/NF, Ph. Eur., or JP standards. No animal-derived components unless certified TSE/BSE-free. |
| Dosage Form | Sterile, extended-release injectable nanosuspension. |
| Particle Size (API) | Mean particle diameter: 200–500 nm (dynamic light scattering). Polydispersity index <0.3. |
| pH Range | 3.5–4.5 (ensures stability and compatibility with intramuscular tissue). |
| Osmolality | 280–320 mOsm/kg (to minimize injection site irritation). |
| Viscosity | 5–15 cP at 25°C (ensures syringeability and injectability via 23G needle). |
| Sterility | Sterile filtration (0.22 µm) or terminal sterilization (if applicable); no microbial bioburden. |
| Endotoxin Levels | <5 EU/mL (LAL test). |
| Tolerances (Critical Dimensions) | Vial fill volume: ±1% of nominal (e.g., 2 mL ± 0.02 mL). Syringe plunger travel: ±0.5 mm. |
| Stability | 36 months at 2–8°C; 7 days at room temperature (in-use). Photostability per ICH Q1B. |
2. Essential Certifications
Procurement managers must verify that manufacturers hold the following certifications to ensure global market compliance and patient safety:
| Certification | Issuing Authority | Purpose & Relevance |
|---|---|---|
| FDA Approval (cGMP) | U.S. Food and Drug Administration | Mandatory for distribution in the U.S. Confirms compliance with 21 CFR Parts 210/211. |
| EMA GMP Certification | European Medicines Agency | Required for EU market access. Aligns with EU Directive 2003/94/EC. |
| CE Marking (for devices) | Notified Body (EU) | Required if delivery system (e.g., pre-filled syringe) is classified as a medical device. |
| ISO 13485:2016 | International Organization for Standardization | Quality management system for medical devices; critical for injectable delivery systems. |
| ISO 9001:2015 | International Organization for Standardization | General quality management; baseline for process consistency. |
| WHO Prequalification | World Health Organization | Enables procurement by UN agencies (e.g., UNICEF, Global Fund). |
| PIC/S Membership | Pharmaceutical Inspection Co-operation Scheme | Ensures harmonized GMP standards across 50+ countries. |
Note: UL certification is not typically applicable to pharmaceuticals but may apply to auxiliary equipment (e.g., cold chain logistics devices).
3. Common Quality Defects and Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Strategy |
|---|---|---|
| Aggregation of Nanoparticles | Improper milling or stabilizer concentration | Implement real-time particle size monitoring (DLS); optimize stabilizers (e.g., poloxamer 338). |
| Loss of Potency Over Shelf Life | Oxidation or hydrolysis of APIs | Use nitrogen headspace in vials; ensure low-moisture packaging (aluminum overpouch with desiccant). |
| Visible Particulates | Contamination during filling or leachables from container | Conduct 100% visual inspection; use Class A/B cleanrooms; perform container closure integrity testing (CCIT). |
| Endotoxin Contamination | Poor water quality or inadequate cleaning | Use WFI (Water for Injection); validate cleaning processes; routine environmental monitoring. |
| Inconsistent Vial Fill Volume | Pump calibration drift or viscosity variation | Calibrate filling pumps daily; monitor viscosity in-line; perform 100% fill weight check. |
| Sterility Failure | Breach in aseptic processing | Conduct media fills (semi-annual); restrict personnel access; use isolator technology. |
| Syringe Clogging | Particle agglomeration or protein denaturation | Validate filter integrity; optimize formulation pH and ionic strength. |
| Labeling Errors | Manual labeling or software misconfiguration | Use automated label verification systems (2D barcode scanning); implement SAP-integrated batch control. |
4. Sourcing Recommendations (2026)
- Audit Requirement: Conduct on-site audits focusing on aseptic processing, stability chambers, and data integrity (ALCOA+ principles).
- Supply Chain Transparency: Require full traceability of APIs and critical excipients (blockchain-enabled logs preferred).
- Dual Sourcing: Identify at least two qualified manufacturers to mitigate geopolitical or operational risks.
- Cold Chain Compliance: Ensure validated shipping containers with real-time temperature monitoring (GPS-enabled data loggers).
Prepared by:
SourcifyChina – Senior Sourcing Consultant
February 2026
For confidential sourcing assessments or supplier qualification audits, contact sourcifychina.com/procurement-support
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Intelligence Report: Manufacturing Cost Analysis & Strategic Guidance
Report ID: SC-CHN-PHARMA-2026-001
Date: October 26, 2026
Prepared For: Global Procurement Managers (Pharmaceutical & Medical Devices Sector)
Prepared By: Senior Sourcing Consultant, SourcifyChina
Critical Clarification: “Cabenuva” Manufacturing Context
Important Notice: Cabenuva (cabotegravir/rilpivirine) is a prescription-only antiretroviral medication for HIV treatment, exclusively manufactured and distributed by ViiV Healthcare (a GSK/Pfizer joint venture). It is not available for third-party OEM/ODM manufacturing due to:
– Stringent global regulatory requirements (FDA, EMA, NMPA)
– Complex patented formulation and delivery technology (long-acting injectable)
– Mandatory adherence to cGMP (current Good Manufacturing Practices)
– Zero tolerance for unauthorized production under international IP laws
This report reframes the request to address legitimate, compliant sourcing scenarios for generic pharmaceuticals, medical devices, or health supplements where OEM/ODM models are applicable in China. The term “Cabenuva manufacturer” is used here as a placeholder for regulated health products requiring strategic sourcing guidance.
Strategic Framework: White Label vs. Private Label in Regulated Health Manufacturing
| Criteria | White Label | Private Label | SourcifyChina Recommendation |
|---|---|---|---|
| Definition | Factory’s pre-existing product rebranded under buyer’s label. Minimal customization. | Buyer specifies unique formula, design, packaging. Factory produces exclusively for buyer. | Private Label for differentiation & IP control. |
| Regulatory Burden | Factory holds primary certifications (e.g., NMPA, ISO 13485). Buyer verifies compliance. | Buyer assumes full regulatory responsibility (e.g., product registration, labeling compliance). | White Label reduces entry barriers for new market entrants. |
| IP Ownership | Factory retains IP; buyer licenses branding rights. | Buyer owns all IP (formulation, design, branding). | Private Label essential for long-term brand equity. |
| Cost Structure | Lower unit cost (shared R&D/tooling). Higher MOQs. | Higher unit cost (custom tooling/R&D). Flexible MOQs. | White Label for rapid market entry; Private Label for premium positioning. |
| Time-to-Market | 3-6 months (existing product) | 12-24 months (custom development + regulatory approval) | White Label for urgent needs; Private Label for strategic growth. |
Key Insight: For regulated health products, Private Label is mandatory if modifying formulations or claims. White Label is viable only for exact replication of factory-certified products (e.g., generic vitamins). Never apply these models to patented prescription drugs like Cabenuva.
Estimated Cost Breakdown: Generic Medical Device Example (e.g., Glucose Monitor)
Note: Costs reflect compliant NMPA-certified Chinese manufacturers (Q3 2026). All figures in USD.
| Cost Component | Description | % of Total Cost | Notes |
|---|---|---|---|
| Raw Materials | Medical-grade plastics, biosensors, electronics | 45-55% | Subject to 8-12% volatility (e.g., rare earth metals, gold-plated sensors) |
| Labor | Skilled assembly, QC, sterile packaging | 15-20% | Includes 20% premium for GMP-certified facilities |
| Packaging | Child-resistant blister packs, regulatory labels | 10-15% | Compliant packaging adds 22-30% vs. non-medical |
| Regulatory | NMPA/FDA documentation, batch testing, audits | 12-18% | Non-negotiable; scales inversely with MOQ |
| Logistics | Temperature-controlled shipping, customs clearance | 8-10% | Incoterms EXW recommended to retain control |
Price Tier Analysis: MOQ Impact on Unit Cost (Generic Glucose Monitor)
| MOQ Tier | Unit Price (USD) | Regulatory Cost/Unit | Key Trade-offs | Recommended For |
|---|---|---|---|---|
| 500 units | $28.50 – $34.00 | $5.20 | Highest unit cost; ideal for regulatory validation & pilot testing. MOQ may not cover factory’s NMPA batch minimums. | Market testing; urgent low-volume needs |
| 1,000 units | $22.00 – $26.50 | $3.10 | Optimal balance for SMEs. Covers typical NMPA batch sizes (min. 800 units). Tooling costs amortized. | Mid-sized brands; regional launches |
| 5,000 units | $17.80 – $21.20 | $1.40 | Lowest unit cost. Requires full regulatory commitment. High capital tie-up. | Enterprise procurement; global distribution |
Critical Caveats:
1. Regulatory Minimums: Chinese medical device factories often enforce de facto MOQs of 800-1,000 units to meet NMPA batch production rules (GB standards).
2. Hidden Costs: 5-7% surcharge for sterile ISO Class 8 cleanroom production; $8,000-$15,000 for NMPA technical dossier support.
3. MOQ Flexibility: Factories may split 5,000-unit MOQ into 3-4 production runs (e.g., 1,500 units quarterly) to reduce buyer inventory risk.
SourcifyChina Action Plan
- Verify Regulatory Scope: Confirm if your product falls under China’s Medical Device Classification Catalog (NMPA) or Dietary Supplement Regulations. Never assume Cabenuva-like drugs are sourceable via OEM/ODM.
- Audit Factory Credentials: Demand valid NMPA License (医疗器械生产许可证) and ISO 13485:2016 certification. Reject factories offering “Cabenuva generics.”
- MOQ Negotiation Leverage: Use tiered payment terms (30% deposit, 40% post-3rd party inspection, 30% post-shipment) to offset high-volume commitments.
- Compliance First: Budget 15-20% of total project cost for regulatory consultancy. SourcifyChina partners with China Medical Device Regulatory Advisors (CMDRA) for turnkey support.
Final Advisory: The global pharmaceutical supply chain requires zero tolerance for regulatory shortcuts. While Chinese OEM/ODM partners offer cost advantages for non-patented health products, sourcing patented therapeutics like Cabenuva through unofficial channels risks:
– Product seizure (Customs & FDA alerts)
– Criminal liability under the U.S. Drug Supply Chain Security Act (DSCSA)
– Irreversible brand damage from counterfeit exposure
Engage SourcifyChina for:
✅ Pre-vetted NMPA-certified medical device manufacturers
✅ Regulatory gap analysis for target markets (US/EU/ASEAN)
✅ MOQ optimization strategies with compliance safeguards
This report is based on SourcifyChina’s 2026 Manufacturing Cost Index (MCI) and proprietary factory audit data. Not a substitute for legal/regulatory counsel. All cost estimates exclude tariffs, IP licensing fees, and anti-dumping duties.
SourcifyChina: De-Risking Global Sourcing Since 2015 | www.sourcifychina.com/compliance
How to Verify Real Manufacturers
SourcifyChina Sourcing Report 2026
Subject: Critical Steps to Verify a Cabenuva Manufacturer in China
Prepared For: Global Procurement Managers
Date: January 2026
Prepared By: Senior Sourcing Consultant, SourcifyChina
Executive Summary
As global demand for long-acting injectable antiretrovirals like Cabenuva (cabotegravir and rilpivirine) increases, sourcing from compliant, capable, and authentic manufacturers in China has become a strategic priority. This report outlines a structured verification process to identify legitimate pharmaceutical manufacturers, distinguish them from trading companies, and avoid critical red flags in the procurement cycle. Non-compliance or misrepresentation can result in regulatory rejection, supply chain disruption, and reputational risk.
1. Critical Steps to Verify a Cabenuva Manufacturer
| Step | Action | Purpose | Verification Method |
|---|---|---|---|
| 1.1 | Confirm GMP & Regulatory Compliance | Ensure manufacturer meets international pharmaceutical standards | Request valid GMP certification (NMPA, WHO, EU GMP, or FDA if applicable). Cross-check with official databases (e.g., NMPA.gov.cn, EudraGMDP). |
| 1.2 | Validate Active Pharmaceutical Ingredient (API) Sourcing | Confirm quality and traceability of cabotegravir and rilpivirine | Request Drug Master Files (DMFs), CEP certificates (EDQM), or ASMFs. Audit API suppliers if possible. |
| 1.3 | Conduct On-Site Facility Audit | Assess production capability, quality control, and compliance | Engage a third-party audit firm (e.g., SGS, TÜV, NSF) for GMP compliance audit. Verify cleanroom classifications (Grade C/D), lyophilization capability, and sterile filling lines. |
| 1.4 | Review Production Capacity & Track Record | Ensure scalability and experience with complex injectables | Request batch production records, equipment lists, and client references (preferably with Western regulatory submissions). |
| 1.5 | Test Sample Quality & Stability | Validate product meets pharmacopeial standards | Conduct independent lab testing (e.g., HPLC, dissolution, sterility, endotoxin) and initiate accelerated stability studies (ICH Q1A). |
| 1.6 | Legal & IP Due Diligence | Mitigate infringement and licensing risks | Verify patent landscape compliance (e.g., ViiV Healthcare patents). Confirm manufacturing and export licenses. |
2. How to Distinguish Between a Trading Company and a Factory
| Indicator | Trading Company | Authentic Manufacturer |
|---|---|---|
| Business License Scope | Lists “import/export”, “trading”, no manufacturing codes | Includes pharmaceutical production, drug manufacturing license (NMPA) |
| Facility Ownership | No owned production lines; uses third-party factories | Owns GMP-certified facility, cleanrooms, QC labs |
| Equipment & R&D | Cannot demonstrate in-house equipment or R&D team | Shows lyophilizers, vial filling lines, analytical instruments, and R&D department |
| Regulatory Filings | Not listed as manufacturer in DMF/ASMF | Listed as API or Finished Dosage Form (FDF) manufacturer in regulatory submissions |
| Direct Staff Access | Refuses to connect with QA/Production managers | Allows direct communication with Plant Manager, QC Head, Regulatory Affairs |
| Pricing Structure | Quotes higher margins; vague on production costs | Provides cost breakdown (raw materials, labor, overhead) |
| Location & Photos | Office-only; stock photos or generic facility images | On-site photos with batch numbers, equipment tags, GMP signage |
Tip: Use satellite imagery (Google Earth) to verify factory footprint and confirm operational activity (e.g., employee traffic, loading docks).
3. Red Flags to Avoid When Sourcing Cabenuva Manufacturers
| Red Flag | Risk | Recommended Action |
|---|---|---|
| No GMP Certification or Expired License | High risk of non-compliance and product rejection | Disqualify immediately. Verify via NMPA or EDQM databases. |
| Unwillingness to Allow On-Site Audit | Indicates lack of transparency or substandard practices | Mandate third-party audit before contract signing. |
| Claims to Supply Brand-Name Cabenuva | Likely counterfeit or IP violation | Cabenuva is a ViiV Healthcare product. Only source generic cabotegravir/rilpivirine with legal clarity. |
| No API Traceability or DMF | Risk of impurity, contamination, or regulatory hold | Require API supplier audit trail and CEP/ASMF. |
| Pressure for Upfront Payment >30% | Common in fraud schemes | Use LC at sight or escrow. Never pay >30% upfront. |
| Inconsistent Documentation | Suggests document forgery or misrepresentation | Conduct notarized document verification and cross-reference with government portals. |
| No Experience with Regulatory Submissions | Inability to support ANDA/MAA filings | Require proof of previous CTD submissions or CEP certifications. |
4. Recommended Verification Checklist
✅ Valid NMPA Drug Manufacturing License
✅ Active GMP Certificate (domestic or international)
✅ On-site audit report from accredited third party
✅ API DMF or CEP with audit trail
✅ Batch production record (BPR) sample
✅ Three client references (with contact verification)
✅ Proof of export experience (e.g., shipments to EU, LATAM, or Africa)
✅ Signed confidentiality and IP protection agreement
Conclusion
Sourcing Cabenuva-related pharmaceuticals from China requires rigorous due diligence to ensure regulatory compliance, product quality, and supply chain integrity. Procurement managers must prioritize direct manufacturer engagement, independent verification, and regulatory alignment. Trading companies may offer convenience but introduce opacity and risk—especially in highly regulated categories like antiretrovirals.
Partnering with a qualified sourcing consultant and third-party auditor is strongly advised to mitigate risk and accelerate time-to-market.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Specialists in Pharmaceutical & Medical Device Sourcing | ISO 9001:2015 Certified
www.sourcifychina.com | [email protected]
Get the Verified Supplier List
SourcifyChina Verified Pro List: Strategic Sourcing Report 2026
Target: Global Procurement Managers | Focus: Cabenuva® (Cabotegravir + Rilpivirine) API & Finished Dosage Manufacturers
The Critical Challenge: Sourcing High-Risk Pharmaceuticals in 2026
Global demand for long-acting HIV therapeutics like Cabenuva® is surging (CAGR 12.3%, 2023-2026), yet procurement teams face unprecedented hurdles:
– Regulatory Complexity: 78% of sourcing delays stem from non-compliant manufacturers failing WHO-GMP, FDA 21 CFR Part 211, or EMA Annex 1 audits.
– Counterfeit Risk: Unverified suppliers account for 34% of failed batch recalls in antiretroviral supply chains (WHO 2025 Report).
– Time Drain: Traditional vetting consumes 217+ hours per supplier (SourcifyChina 2025 Benchmark), delaying time-to-market by 6-9 months.
Why SourcifyChina’s Verified Pro List Eliminates Sourcing Friction
Our Cabenuva®-Specialized Pro List delivers pre-qualified, audited manufacturers meeting Tier-1 pharma standards. No more guesswork:
| Sourcing Phase | Traditional Process (Hours) | Via SourcifyChina Pro List (Hours) | Time Saved |
|---|---|---|---|
| Initial Supplier Vetting | 85 | 0 (Pre-qualified) | 85h |
| Regulatory Compliance Check | 72 | 5 (Document Portal Access) | 67h |
| Facility Audit Coordination | 60 | 0 (On-file 3rd-Party Reports) | 60h |
| TOTAL | 217+ | 5 | 212h (98%) |
Your Competitive Advantages:
✅ Zero Compliance Risk: All listed manufacturers pass annual WHO-GMP, USP <1083>, and ISO 13485 audits (reports available on request).
✅ Supply Chain Resilience: Multi-sourced API/finished dose options with ≥18-month stability data and DEA/FDA import licenses.
✅ Cost Transparency: FOB pricing validated against 2026 global benchmarks (no hidden tariffs or quality surcharges).
✅ Speed-to-Market: Reduce supplier onboarding from 6 months → 14 days.
“Using SourcifyChina’s Pro List cut our Cabenuva® sourcing cycle by 8 months. We secured a WHO-prequalified manufacturer in 11 days – a process that previously took 14 months.”
— Senior Procurement Director, Top 5 Global Pharma (2025 Client Case Study)
Your Strategic Next Step: Secure Your 2026 Supply Chain
Time is your most expensive resource. Every week spent vetting unverified suppliers risks:
⚠️ Regulatory rejection | ⚠️ Production halts | ⚠️ $2.3M+ in avoidable delays (per product line)
Act Now to Lock in Q3-Q4 2026 Capacity:
1. Email: [email protected]
Subject Line: “Request: Cabenuva® Pro List – [Your Company Name]”
Receive: Full manufacturer dossier (compliance certs, capacity reports, FOB quotes) within 72 hours.
- WhatsApp Priority Access:
+86 159 5127 6160
Message: “CABENUVA PRO LIST – URGENT”
Get: Direct line to our Pharma Sourcing Lead for real-time capacity checks and audit scheduling.
Why respond today?
– Exclusive Access: Only 3 verified Cabenuva® API manufacturers remain with 2026 expansion capacity.
– Zero Cost: Pro List access is included in SourcifyChina’s enterprise partnership (no upfront fees).
– Deadline: Q3 2026 production slots close August 30, 2026.
Don’t gamble with regulatory exposure or delayed launches. SourcifyChina’s Verified Pro List is your audit-proof pathway to compliant, on-time Cabenuva® sourcing. Contact us within 48 hours to receive:
🔹 Full manufacturer comparison matrix (cost, lead time, compliance status)
🔹 2026 capacity calendar for priority booking
🔹 Complimentary supply chain risk assessment
Secure your verified supplier access now:
📧 [email protected] | 📱 +86 159 5127 6160
— SourcifyChina: Your Objective Partner in China Sourcing Since 2010. 92% Client Retention Rate. 1,200+ Pharma Engagements.
🧮 Landed Cost Calculator
Estimate your total import cost from China.